This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cyclacel (CYCC) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
We expect Cyclacel (CYCC) to provide updates on its pipeline when it releases fourth-quarter 2019 results.
Epizyme (EPZM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
We expect Epizyme (EPZM) to provide commercialization updates on its sarcoma drug when it releases fourth-quarter 2019 earnings.
What's in Store for Aimmune (AIMT) This Earnings Season?
by Zacks Equity Research
Aimmune (AIMT) is likely to provide an update on Palforzia's launch plans during Q4 investors' call. The drug gets an approval in January 2020 for the treatment of peanut allergy.
Akorn (AKRX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Akorn's (AKRX) fourth-quarter 2019 results are likely to reflect a decline in sales volume due to stiffening competition.
What's in Store for Corcept (CORT) This Earnings Season?
by Zacks Equity Research
During Corcept's (CORT) Q4 earnings call, investor focus will be on the sales uptake of its Cushing's syndrome drug Korlym and other pipeline updates.
Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar
by Zacks Equity Research
The biotech sector witnesses pipeline updates from the annual ASH meet.
Sage Therapeutics (SAGE) in Focus: Stock Moves 7.1% Higher
by Zacks Equity Research
Sage Therapeutics (SAGE) shares rose more than 7% in the last trading session, amid huge volumes.
Sage Therapeutics' Depression Drug Fails in Study, Stock Down
by Zacks Equity Research
Sage Therapeutics' (SAGE) phase III study on pipeline candidate SAGE-217 for the treatment of major depressive disorder fails to meet the primary endpoint.
VistaGen's (VTGN) Major Depressive Disorder Drug Disappoints
by Zacks Equity Research
VistaGen (VTGN) announces disappointing results from the ELEVATE study on MDD candidate, AV-101.
5 Biotech Stocks Set to Beat Q3 Earnings Estimates
by Kinjel Shah
Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.
Moving Average Crossover Alert: Sage Therapeutics
by Zacks Equity Research
Sage Therapeutics could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Earnings Preview: Sage Therapeutics (SAGE) Q2 Earnings Expected to Decline
by Zacks Equity Research
Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ligand Grants Preclinical Candidate Rights to UK-based Firm
by Zacks Equity Research
Ligand (LGND) grants exclusive worldwide rights to a pre-clinical cancer candidate discovered using Vernalis Design platform to Cumulus Oncology.
The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage
Biotech Stocks Outperform During Inversions: 5 Must Watch
by Tirthankar Chakraborty
An inverted yield curve signals a recession but it is often bullish for biotech stocks.
Ligand (LGND) Takes a Hit on Citron's Negative Research Report
by Zacks Equity Research
Ligand (LGND) plunges as short-seller Citron Research questions the company's business prospects.
Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus
by Zacks Equity Research
It was a busy week for the biotech sector with most companies gaining on M&A activity. The annual J.P. Morgan Healthcare conference were also a key area of focus.
Implied Volatility Surging for Sage Therapeutics (SAGE) Stock Options
by Zacks Equity Research
Sage Therapeutics (SAGE) needs investors to pay close attention to the stock based on moves in the options market lately.
Company News For Jun 13, 2018
by Zacks Equity Research
Companies In The News are: TSLA,SAGE,RH,PLAY
Sage Therapeutics Soars: Stock Adds 7.1% in Session
by Zacks Equity Research
Sage Therapeutics (SAGE) was a big mover last session, as the company saw its shares rise more than 7% on the day.
Implied Volatility Surging for Sage Therapeutics (SAGE) Stock Options
by Zacks Equity Research
Surging implied volatility makes Sage Therapeutics (SAGE) stock lucrative to the option traders.
Implied Volatility Surging for Sage Therapeutics, Inc. (SAGE) Stock Options
by Zacks Equity Research
Surging implied volatility makes Sage Therapeutics, Inc. (SAGE) stock lucrative to the option traders.
Options Traders Expect Huge Moves in Sage Therapeutics (SAGE) Stock
by Zacks Equity Research
Options Traders Expect Huge Moves in Sage Therapeutics (SAGE) Stock on the back of its high level of implied volatility.
5 Drug Stocks for Your Portfolio this World Health Day
by Arpita Dutt
With "Depression: let's talk" being this year's World Health Day campaign slogan, here's a look at 5 companies developing treatments for various types of depression.
Are Options Traders Betting on a Big Move in Sage Therapeutics (SAGE) Stock?
by Zacks Equity Research
Options Traders are Betting on a Big Move in Sage Therapeutics (SAGE) Stock on the back of its huge implied volatility.